B and T cell responses to the 3rd and 4th dose of the BNT162b2 vaccine in dialysis patients

Younes Bathisha Ziv Medcal Center, Safed, Israel;b Azrieli Faculty of Medicine, Bar-Ilan University, Safed, IsraelView further author information

Neta Tuviaa Ziv Medcal Center, Safed, IsraelCorrespondence[email protected]
View further author information

Elizabeth Eshela Ziv Medcal Center, Safed, IsraelView further author information

Tali Tal Langea Ziv Medcal Center, Safed, IsraelView further author information

Christiane Sigrid Eberhardtc Department for Pediatrics, Gynecology and Obstetrics, Faculty of Medicine, University of Geneva, Geneva, Switzerland;d Center for Vaccinology, University Hospitals of Geneva, Geneva, Switzerland;e Center for Vaccinology and Neonatal Immunology, Department of Pathology-Immunology, Faculty of Medicine, University of Geneva, Geneva, SwitzerlandView further author information

Michael Edelsteina Ziv Medcal Center, Safed, Israel;b Azrieli Faculty of Medicine, Bar-Ilan University, Safed, IsraelView further author information

Kamal Abu-Jabala Ziv Medcal Center, Safed, Israel;b Azrieli Faculty of Medicine, Bar-Ilan University, Safed, IsraelView further author information

show all

B and T cell responses to the 3rd and 4th dose of the BNT162b2 vaccine in dialysis patients

Supplementary material_HVI_revised.docx

Information for

Open access

Opportunities

Help and information

Your download is now in progress and you may close this window

Login or register to access this feature

B and T cell responses to the 3rd and 4th dose of the BNT162b2 vaccine in dialysis patients

Supplementary material_HVI_revised.docx

Related research

To cite this article:

Download citation

Information for

Open access

Opportunities

Help and information

Keep up to date